Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Prostate Cancer | Current Treatment: Physician Insights | US | 2023

Login to access report north_east
Contact sales account_box

Hormonal therapy is the cornerstone of drug treatment for prostate cancer in all patient populations. Abiraterone and Xtandi (Pfizer / Astellas Pharma) dominate the metastatic castrate-resistant prostate cancer (mCRPC) market and account for sizable market shares in the metastatic hormone-sensitive prostate cancer (mHSPC) setting. They compete with other next-generation hormonal therapies like Erleada (Janssen) and Nubeqa (Bayer HealthCare), two brands initially approved for nonmetastatic castrate-resistant prostate cancer (nmCRPC). The PSMA-targeted radioligand therapy Pluvicto (Novartis), which the FDA approved in March 2022, is having an impact on the treatment of mCRPC. The PARP inhibitors Lynparza (AstraZeneca) and Rubraca (Clovis Oncology) offer other biomarker-driven options for mCRPC treatment, and Xofigo (Bayer HealthCare) and Jevtana (Sanofi) are other nonhormonal treatment options for mCRPC, particularly in later lines.

Questions Answered

  • What are the drug-treatment rates across clinically and commercially relevant prostate cancer patient populations?
  • What is the uptake of the PSMA radioligand therapy Pluvicto in mCRPC to date?
  • What are the patient shares of key therapies in commercially relevant prostate cancer patient populations?
  • What are the main drivers of and obstacles to the uptake of current therapies in select hormone-sensitive and castrate-resistant patient segments?

Product Description

Current Treatment: Physician Insights provides physician insights ontreatment dynamics, prescribing behavior, and drivers of brand useso that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Markets covered: United States

Primary research: Survey of 100 medical oncologists and urologists (50 of each specialty) in the United States fielded in May 2023.

Key drugs covered: Abiraterone, Xtandi, Erleada, Nubeqa, Orgovyx, Pluvicto, Provenge, Xofigo, Jevtana, Lynparza, Rubraca, others

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Systemic Lupus Erythematosus – Access & Reimbursement – Access & Reimbursement – Systemic Lupus Erythematosus (US)
The U.S. systemic lupus erythematosus (SLE) therapy market is largely genericized and off-label. With the exception of GSK’s Benlysta, the firstagents approved for the indication in almost 60…
north_east
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Heart failure with reduced ejection fraction (HFrEF) occurs when the left ventricular ejection fraction (LVEF) is 40% or less. Drug treatment for HFrEF is well established and supported by…
north_east
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Preserved Ejection Fraction (US)
Heart failure with preserved ejection fraction (HFpEF) occurs when the left ventricular ejection fraction (LVEF) is 50% or more. Even though physicians’ understanding of the disease’s…
north_east
Report
Membranous Nephropathy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Primary membranous nephropathy (pMN), the most common type of MN, is a rare autoantibody-mediated autoimmune kidney disease. Although it is one of the leading causes of nephrotic syndrome in…
north_east
Report
Migraine – Access & Reimbursement – Access & Reimbursement – Migraine Prophylaxis (US)
Preventive migraine care in the United States continues to evolve. Since 2018, CGRPtargeting mAbs (Aimovig, Emgality, Ajovy, Vyepti) and oral gepants (Nurtec ODT, Qulipta) have become established…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east